* +5%/+3% adj. EBITDA vs ABGSCe/Infront cons in Q3 * Cons estimates likely up 1-2% on adj.
Redeye provides an update on Scandinavian ChemoTech following the Q3 2025 report.
NoHo Partners' Q3 2025 was challenging, mainly due to Norway, where the market keeps declining and t...
* EBIT adj. SEK 7.2m (9.4m), vs. ABGSCe of SEK 14m * We lower '26e-'27e EBIT adj.
* Q3 beat our expectations handily, EBITA 29% above * Raise '26e-'27e EBITA 15-14% on higher margin ...
* Q3e Paper EBIT of ~PLN 5m * Challenging markets * Fair value range of SEK 17-60 Q3e Paper EBIT of ...
Thunderful did not release any major titles during the third quarter.
Redeye comments on Freemelt’s Q3 report, which was slightly better than we expected.
* Sales -9% & EBIT adj. SEK 7m below vs. ABGSCe * EBIT impacted by SEK +6 m one-off gain from Q3’24 ...
Redeye provides an initial comment on Serstech’s Q3 2025 report.
Redeye adjusts its estimates and valuation for Fluoguide's directed share issue.
Aspo’s Q3 results were in the end neutral; both ESL and Telko can improve more next year, when they ...
Redeye provides a research update following IRLAB's recent Q3 report.
NoHo Partners reported Q3 EBIT of EUR 7.6m from continuing operations (down 13% y/y), 12% below Vara...
BioInvent will present new data from BI-1206 (triplet) and BI-1808 (T-cell lymphoma) at ash.
